Search - tctmd.com

Displaying 261 - 280 of 373

Sort: Relevancy | Date

News Conference News ACC 2018

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Yael L. Maxwell

March 19, 2018

News Daily News

‘High Index of Suspicion’ First Step in Successful Management of SCAD

Michael O'Riordan

February 27, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

Presentation TTT 2018

Use of NOAC in Coronary Artery Disease

Presenter: Tsung-Hsien Lin

January 14, 2018

News Features

Cardiologists Treating Syrian Refugees Call Missions an ‘Addictive’ Passion That Saves Lives

Yael L. Maxwell

January 12, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

Shelley Wood

November 29, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Caitlin E. Cox

November 14, 2017

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

Advertisement

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

‘High Index of Suspicion’ First Step in Successful Management of SCAD

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Use of NOAC in Coronary Artery Disease

Cardiologists Treating Syrian Refugees Call Missions an ‘Addictive’ Passion That Saves Lives

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

TCTMD’s Top 10 Most Popular Stories for November 2017

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

TCTMD’s Top 10 Most Popular Stories for August 2017

ESC Updates Guidelines for Treating STEMI Patients

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content